Gβγ that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein

Journal of Neurobiology

Volumn 66, Issue 12, 2006, Pages 1302-1310

  Wang, Hoau Yan ^a   Burns, Lindsay H ^b  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b Pain Therapeutics Inc   (United States)

Author keywords

G protein; Isotyping; Morphine; Naloxone; Signaling

Indexed keywords

ADENYLATE CYCLASE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE; NALOXONE; OPIATE; ADENYLYL CYCLASE 2; ADENYLYL CYCLASE 4; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; ISOPROTEIN; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; HUMAN; IMMUNOPRECIPITATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; ANIMAL; COMPARATIVE STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ADENYLATE CYCLASE; ANALGESICS, OPIOID; ANIMALS; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; GTP-BINDING PROTEIN ALPHA SUBUNITS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; GTP-BINDING PROTEIN BETA SUBUNITS; GTP-BINDING PROTEIN GAMMA SUBUNITS; MALE; MORPHINE; NARCOTIC ANTAGONISTS; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 33750807737     PISSN: 00223034     EISSN: 10974695     Source Type: Journal    
DOI: 10.1002/neu.20286     Document Type: Article

References (40)

1. Cai G, Wang H-Y, Friedman E. 2002. Increased dopamine receptor signaling and dopamine receptor-protein coupling in denervated striatum. J Pharmacol Exp Ther 302:1105-1112.
2. Chakrabarti S, Regec A, Gintzler AR. 2005. Biochemical evidence that the μ opioid receptor associates with Gs, which is augmented following chronic morphine exposure. In: Society for Neuroscience. Washington, D.C.
3. Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. 2005. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 6:392-399.
4. Crain SM, Shen K-F. 1990. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci 11:77-81.
5. Crain SM, Shen K-F. 1992. After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside. Brain Res 575:13-24.
6. Crain SM, Shen K-F. 1995. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA 92:10540-10544.
7. Crain SM, Shen K-F. 2000. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84:121-131.
8. Crain SM, Shen K-F. 2001. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res 888:75-82.
9. Cruciani RA, Lussier D, Miller-Saultz D, Arbuck DM. 2003. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Management 25:491-494.
10. Finn AK, Whistler JL. 2001. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 32:829-839.
11. Friedman E, Butkerait P, Wang H-Y. 1993. Analysis of receptor-stimulated and basal guanine hucleotide binding to membrane G proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 214:171-178.
12. Friedman E, Wang H-Y. 1996. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. J Neurochem 67:1145-1152.
13. Gan TJ, Ginsberg B, Glass PSA, Fortney J, Jhaveri R, Perno R. 1997. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 87:1075-1081.
14. Gintzler AR, Chakrabarti S. 2001. Opioid tolerance and the emergence of new opioid receptor-coupled signaling. Mol Neurobiol 21:21-33.
15. Gintzler AR, Chan WC, Glass J. 1987. Evoked release of methionine-enkephalin from tolerant/dependent enteric ganglia: paradoxical dependence on morphine. Proc Natl Acad Sci USA 84:2537-2539.
16. Hamman S, Wala E, Rebel A, Lock R. 2004. Selective antagonism of excitatory opioid receptor systems: A pilot clinical study demonstrating enhancement of morphine analgesia by low-dose naloxone in female patients undergoing elective laparotomy. In: American Society of Anesthesiologists Annual Meeting. Las Vegas, NV.
17. Ikeda K, Kobayashi T, Kumanishi T, Niki H, Yano R. 2000. Involvement of G-protein-activated inwardly rectifying K (GIRK) channels in opioid-induced analgesia. Neurosci Res 38:113-116.
18. Insel P, Head B, Patel H, Roth D, Bundey R, Swaney J. 2005. Compartmentation of G-protein-coupled receptors and their signalling components in lipid rafts and caveolae. Biochem Soc Trans 33:1131-1134.
19. Jin LQ, Wang H-Y, Friedman E. 2001. Stimulated D(1) dopamine receptors couple to multiple Galpha proteins in different brain regions. J Neurochem 78:981-990.
20. Joshi GP, Duffy L, Chehade J, Wesevich J, Gajraj N, Johnson ER. 1999. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology 90:1007-1011.
21. Lavine N, Ethier N, Oak J, Pei L, Liu F, Trieu P, Rebois R, et al. 2002. G Protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. J Biol Chem 277:46010-46019.
22. Leri F, Burns LH. 2005. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem Behav 82:252-262.
23. Nestler EJ. 2001. Molecular neurobiology of addiction. Am J Addict 10:201-217.
24. Olmstead MC, Burns LH. 2005. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology 181:576-181.
25. Powell KJ, Abul-Husn NS, Jhamandas A, Olmstead MC, Beninger RJ, Jhamandas K. 2002. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther 300:588-596.
26. Saegusa H, Kurihara T, Zong S, Minowa O, Kazuno A, Han W, Matsuda Y, et al. 2000. Altered pain responses in mice lacking α1E subunit of the voltage-dependent Ca2+ channel. Proc Natl Acad Sci USA 97:6132-6137.
27. Shen KF, Crain SM. 1989. Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res 491:227-242.
28. Shen K-F, Crain SM. 1990. Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors. Brain Res 525:225-231.
29. Shen K-F, Crain SM, Moate P, Boston R, de Kater AW, Schoenhard GL. 2002a. PTI-555, reverses and prevents morphine-induced tolerance and naloxone-precipitated withdrawal in mice chronically treated with morphine. J Pain 3:50.
30. Shen K-F, Crain SM, Moate P, Boston R, de Kater AW, Schoenhard GL. 2002b. PTI-801, a novel formulation of oxycodone, shows absence of tolerance, physical dependence and naloxone-precipitated withdrawal effects in mice. J Pain 3:49.
31. Sim LJ, Selley DE, Dworkin SI, Childers SR. 1996. Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16:2684-2692.
32. Tang W-J, Gilman AG. 1991. Type specific regulation of adenylyl cyclase by G protein beta gamma subunits. Science 254:1500-1503.
33. Wang H-Y, Friedman E. 1999. Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes. Neuropharmacology 38:403-414.
34. Wang H-Y, Friedman E, Olmstead MC, Bums LH. 2005. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in Mu opioid receptor-G protein coupling and Gβγ signaling. Neuroscience 135:247-261.
35. Wang L, Gintzler AR. 1997. Altered mu-opiate receptor-G protein signal transduction following chronic morphine exposure. J Neurochem 68:248-254.
36. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. 2006. Oxytrex minimizes physical dependence while providing effective analgesia: A randomized controlled trial in low-back pain. Submitted.
37. Yoburn BC, Billings B, Duttaroy A. 1993. Opioid receptor regulation in mice. J Pharmacol Exp Ther 265:314-320.
38. Yoshimura M, Wu PH, Hoffman PL, Tabakoff B. 2000. Overexpression of type 7 adenylyl cyclase in the mouse brain enhances acute and chronic actions of morphine. Mol Pharmacol 58:1011-1016.
39. Zhang S-P, Wang H-Y, Lovenberg T, Codd E. 2001. Functional studies of bradykinin receptors in Chinese hamster ovary cells stably expressing the human B2 bradykinin receptor. Internat Immunopharmacol 1:955-965.
40. Zhen X, Torres C, Wang H-Y, Friedman E. 2001. Protein phosphatase 1 regulates brain D1A dopamine receptor phosphorylation: Role in dopaminergic dysfunction after in utero cocaine exposure. J Neurosci 21:9160-9167.